Nanobiotix SA

PAR:NANO

Nanobiotix is a French biotechnology company focused on cancer treatment. Its main product is a nanoparticle-based therapy that is designed to be injected into a tumor and activated by radiotherapy, with the goal of making radiation kill more cancer cells while limiting damage to healthy tissue. The company is still building this into an approved medical business rather than selling a broad range of medicines. Its main customers are not patients directly, but hospitals, cancer doctors, and larger pharmaceutical partners that help test, develop, or commercialize the therapy. Nanobiotix makes money through collaboration agreements, licensing deals, and development payments tied to its technology, rather than through large-scale drug sales. If the product reaches the market, future revenue would also come from sales or royalties tied to its cancer treatment platform. What makes Nanobiotix different is that it is more of a targeted technology developer than a traditional drugmaker. It sits at the intersection of nanomedicine and oncology, supplying a treatment approach that other companies or medical centers can pair with radiation therapy. That gives it a business model built around partnering, clinical development, and intellectual property rather than running a large commercial sales force.